Premium
Establishment and characterization of a plasma cell leukaemia cell line dependent for growth on IL‐6 and a bi‐phenotypic subclone dependent upon both IL‐3 and IL‐6
Author(s) -
Kobayashi M.,
Miyagishima T.,
Imamura M.,
Maeda S.,
Gotohda Y.,
Iwasaki H.,
Sakurada K.,
Miyazaki T.
Publication year - 1991
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1991.tb04419.x
Subject(s) - recombinant dna , cd38 , cell culture , microbiology and biotechnology , biology , cancer research , immunology , biochemistry , stem cell , genetics , gene , cd34
Summary A human plasma cell leukaemia cell line (HSM‐2) and a subclone (HSM‐2.3) have been established from the bone marrow of a patient with bi‐phenotypic leukaemia. Proliferation assays using a variety of cytokines demonstrated that HSM‐2 proliferated in response to recombinant interleukin‐6 (rIL‐6), but did not respond to rIL‐1, rIL‐2, rIL‐3, rIL‐4, rIL‐5, recombinant granulocyte‐colony stimulating factor (rG‐CSF), or recombinant granulocyte‐macrophagecolony stimulating factor (rGM‐CSF), and that HSM‐2.3 responded to rIL‐3 and rIL‐6. HSM‐2 expressed the CD38 (OKT10), PCA‐1, cytoplasmic‐IgM, and surface kappa light chain. HSM‐2.3 expressed the CD14 (My4), CD33 (My9). CD38 (OKT10), CD19 (B4), CD24 (OKB2), CD10 (J5), PCA‐1. HSM‐2 and HSM‐2.3 are useful tools for analysing the possible role of IL‐3 and IL‐6 in the oncogenesis of plasma cell leukaemia.